MedTrace Logo

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

NCT00502294 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2009-06-25

No results posted yet for this study

Summary

To compare the efficacy of visilizumab at 5 mcg/kg/day administered intravenously (IV) on Days 1 and 2 to placebo in subjects with IVSR-UC.

Conditions

  • Intravenous Steroid-Refractory Ulcerative Colitis

Interventions

DRUG

Visilizumab (HuM291; Nuvion®)

Sponsors & Collaborators

  • PDL BioPharma, Inc.

    collaborator INDUSTRY

  • Facet Biotech

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00502294 on ClinicalTrials.gov